

(中文節譯文僅供參考，與原文相較可能不盡完整或有歧異，如有疑義應以英文本為準。)

(節譯文)

宏利環球基金

可變資本投資公司

登記營業處所：31, Z.A. Bourmicht, L-8070 Bertrange,
Grand Duchy of Luxembourg

此乃重要文件，謹請台端立即注意。若台端有任何疑問，應尋求獨立專業之建議。本公司董事對本通知所載資訊之準確性承擔全部責任，並於進行一切合理查詢後確認，根據其所知及所信，並無因遺漏其他事實而致使任何誤導陳述之情形。

致股東通知書

(下稱「本通知」)

2026年5月5日

親愛的股東，

謹致函通知您有關宏利環球基金之特定變更(下稱「本公司」)。

除另有說明者外，相關變更將反映於本公司2026年7月之修訂版公開說明書中(下稱「修訂版公開說明書」)。本通知旨在摘要相關變更以便您參考，應與本公司現行版2026年4月之公開說明書(下稱「公開說明書」)及如可得時，與修訂版公開說明書之全文(其內容包括完整且詳盡之變更相關資訊)一併閱讀。

除另有定義外，本通知所使用之詞彙及用語應與公開說明書所定義者具有相同意義。

本公司董事會(下稱「董事」或「董事會」)已決定，自2026年7月10日起(下稱「生效日」)(除另有說明者外)，就本公司實施下列變更係屬適當：

1. [略譯]

2. 其他雜項更新

亦請注意修訂版公開說明書以下事項之更新：

(中文節譯文僅供參考，與原文相較可能不盡完整或有歧異，如有疑義應以英文本為準。)

- (a) 加強公開說明書中附錄二(法定及一般資訊)中與潛在利益衝突相關之揭露；
- (b) 變更宏利投資管理(歐洲)有限公司(Manulife Investment Management (Europe) Limited)之註冊辦公室之地址為 4th Floor, One Strand, London WC2N 5HR, United Kingdom；
- (c) 管理公司董事會之變動；及
- (d) 其他加強及/或揭露之簡化、庶務性、編輯性及/或釐清性之更新。

[略譯]

就上述其他變更事項而言，如您不同意該等變更，您得依據募集文件之規定，申請買回或將您於相關子基金之持股轉換為任何其他子基金中相同級別或類別之股份，惟須支付轉換費用，但毋須支付買回費用。然而，您的銀行或財務顧問可能就該等轉換/買回指示向您收取相關費用。如您有任何疑問，建議您聯絡您的銀行、分銷商或財務顧問。

您僅得將您的持股轉換為同一子基金或其他子基金中相同級別或類別之股份，且該等子基金須為依相關募集文件之規定，於您所在司法管轄區供募集或銷售者；且該等轉換須符合所有適用之最低首次投資金額及最低持有金額之要求，並應符合投資人之資格條件。有關各級別特性之詳細內容，請參閱公開說明書。並提醒您就任何替代投資選項之適合性自行尋求建議。

如選擇買回，買回所得款項將依公開說明書之規定支付給您。如選擇轉換，轉換所得款項將依公開說明書之規定，按適用之股份價格，用以購買您所指定子基金之股份。您的股份如進行轉換或買回，可能影響您的稅務狀況。因此，建議您就您所屬國籍、住所或居住地所在國家可能適用之任何稅負，尋求獨立專業建議。

一般說明

[略譯]

如您就本通知書中所載之任何事項有任何疑問或需任何更進一步之資訊，您得於正常辦公時間內，隨時以電話：(352) 45 14 14 316 或傳真：(352) 45 14 14 850，

(中文節譯文僅供參考，與原文相較可能不盡完整或有歧異，如有疑義應以英文本為準。)

與本公司之行政管理人 Citibank Europe plc 盧森堡分行 (Citibank Europe plc, Luxembourg Branch) 聯絡，或聯絡您的銀行、分銷商或財務顧問。

誠摯地

董事會

代表宏利環球基金

Manulife Global Fund
Société d'investissement à capital variable
Registered office: 31, Z.A. Bourmicht, L-8070 Bertrange
Grand Duchy of Luxembourg

This document is important and requires your immediate attention. If in doubt, you should seek independent professional advice. The Directors of the Company accept full responsibility for the accuracy of the information contained in this Notice and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief there are no other facts the omission of which would make any statement misleading.

Notice to Shareholders
("Notice")

5 May 2026

Dear Shareholder,

We are writing to inform you of certain changes to the Manulife Global Fund (the "**Company**").

Unless otherwise specified below, these changes will be reflected in the revised Prospectus of the Company (and where applicable and for Hong Kong Shareholders only, the revised Hong Kong Covering Document) (collectively, the "**Revised Prospectus**") to be dated July 2026. This Notice, which summarizes the changes for your ease of reference, should be read in conjunction with the current Prospectus of the Company dated April 2026 (and where applicable and for Hong Kong Shareholders only, the current Hong Kong Covering Document dated April 2026) (collectively, the "**Prospectus**") and, when available, the full text of the Revised Prospectus (which contains full and complete information about these changes).

Words and phrases used in this Notice shall, unless otherwise provided, have the same meanings as are ascribed to them in the Prospectus.

The board of directors of the Company (the "**Directors**" or the "**Board**") has decided that it is appropriate to implement the following changes with respect to the Company with effect from 10 July 2026 (the "**Effective Date**") (unless otherwise specified below):

1. *Repositioning of Asian Small Cap Equity Fund*

With a view to providing investors with a product with a thematic focus on the fast-growing innovation and technology sectors in order to capture more attractive returns, thus attracting more capital inflows from investors to further grow the size of the Sub-Fund, thereby enhancing fund management efficiency of the Sub-Fund, the investment objective of Asian Small Cap Equity Fund will be changed such that the Sub-Fund will aim to provide long-term capital growth for investors who hold a long term investment view and are prepared to accept significant fluctuations in the value of their investments, by investing primarily in equity and equity related securities of innovation and/or technology companies which are incorporated, located or listed, or have significant business interests, in the Asia Pacific region ("**Asia Pacific Innovation Companies**").

The investment policy will also be amended such that at least 70% of the Sub-Fund's net assets will be invested in equity and equity related securities of Asia Pacific Innovation Companies.

As a result, the Sub-Fund may have direct and/or indirect exposure to companies which are involved in, without limitation, the artificial intelligence value chain, biotechnology, and the

development and production of semiconductors and related equipment.

In addition, Shareholders should note the following key changes to the investment policy from the Effective Date onwards:

- (a) the Sub-Fund may invest up to 10% of its net assets in UCITS (undertaking for collective investment in transferable securities) and other UCIs (undertaking for collective investment) in accordance with Article 41(1)(e) of the 2010 Law;
- (b) the Sub-Fund will no longer be subject to any limitation on the portion of its net assets that may be invested in issuers of any market capitalisation (although securities of small and medium sized companies may represent, at times, more than 30% of the Sub-Fund's net assets due to the nature of its investment portfolio);
- (c) the Sub-Fund may, from time to time, invest more than 30% of its net assets in companies in the following sectors: information technology (including hardware and software), industrials, communication services, consumer discretionary and healthcare;
- (d) the Sub-Fund may, from time to time, invest more than 30% of its net assets directly in certain China A-Shares listed on the SSE or the SZSE via Shanghai-Hong Kong Stock Connect or Shenzhen-Hong Kong Stock Connect respectively; and
- (e) in times of extreme market volatility or during severe adverse market conditions, the Sub-Fund will have the flexibility to temporarily hold a substantial portion (up to 40%) of its assets in cash or cash equivalents, or invest in short-term money market instruments for the preservation of the value of the assets in the investment portfolio.

Following the changes to the investment objective and policy of the Sub-Fund (the "**Repositioning**"), the Sub-Fund will no longer compare its performance against nor will it be managed in reference to any benchmark.

As a result of the Repositioning, the Sub-Fund will be re-named as "**Asia Innovation Fund**" from the Effective Date, to reflect its new investment focus.

The Investment Manager is expected to commence the rebalancing of the Sub-Fund's portfolio approximately 2 weeks prior to the Effective Date (the "**Rebalancing Period**"). In light of the differences in the investment objective and policy of the Sub-Fund prior to and after the Repositioning, the proportion of assets which are subject to rebalancing is expected to be substantial. Investors should be aware that during the Rebalancing Period, the Sub-Fund may not be able to fully adhere to its current investment objective and policy.

The legal and administrative expenses that will be incurred in connection with the Repositioning described above are approximately USD35,000, which will be borne by Asian Small Cap Equity Fund.

2. Other miscellaneous updates

Please also take note of the following miscellaneous updates to the Revised Prospectus (and where applicable, the Hong Kong Covering Document):

- (a) enhancements of disclosures relating to potential conflicts of interests under Appendix II (*Statutory and General Information*) of the Prospectus;
- (b) change of registered office of Manulife Investment Management (Europe) Limited to 4th Floor, One Strand, London WC2N 5HR, United Kingdom;
- (c) change(s) to the board of directors of the Management Company; and
- (d) other enhancement and/or simplification of disclosures, administrative, editorial and/or clarificatory updates.

For Shareholders in Asian Small Cap Equity Fund only, if you do not agree with the changes described in section 1, you may apply to redeem or to switch your holding in Asian Small Cap Equity Fund to Shares of the same Class or Category in any other Sub-Fund(s), free of any switching charges or redemption charges, until 26 June 2026. In respect of other changes described above, if you do not agree with such changes, you may apply to redeem or to switch your holding in the relevant Sub-Fund(s) to Shares of the same Class or Category in any other Sub-Fund(s), subject to switching charges but free of redemption charges, in accordance with the Offering Documents. However, your bank or financial adviser may charge you fees in respect of such switching/redemption instructions. You are advised to contact your bank, distributor or financial adviser should you have any questions.

You can only switch your holding into Shares of the same Class or Category in the same Sub-Fund or another Sub-Fund, which is offered or sold in your jurisdiction pursuant to the provisions of the relevant offering documents, and such switch is subject to all applicable minimum initial investment amount and minimum holding requirements as well as investor eligibility criteria being complied with. Please refer to the Prospectus for further details of the features of each Class. You are reminded to seek your own advice as to the suitability of any alternative investment option.

In the case of redemption, the redemption proceeds will be paid to you in accordance with the provisions of the Prospectus. In the case of a switch, the conversion proceeds will be utilised to purchase Shares of Sub-Fund(s) specified by you at the share price(s) applicable in accordance with the provisions of the Prospectus (and for Hong Kong Shareholders only, the Hong Kong Covering Document). A switch or redemption of your Shares may affect your tax position. You should therefore seek independent professional advice on any applicable tax in the country of your respective citizenship, domicile or residence.

General

For Hong Kong Shareholders Only: The Prospectus, the Hong Kong Covering Document and the product key fact statements of each Sub-Fund are available during usual business hours on any weekday (Saturdays and public holidays excepted) at the office of the Hong Kong Representative free of charge and are also available at www.manulifeim.com.hk*

Should you have any questions or require any further information about any of the matters set out in this Notice, you may contact the Administrator of the Company, Citibank Europe plc, Luxembourg Branch, at telephone number (352) 45 14 14 316 or fax number (352) 45 14 14 850 or the Hong Kong Distributor, Manulife Investment Management (Hong Kong) Limited, at telephone number (852) 2108 1110 or fax number (852) 2810 9510 at any time during normal business hours, or your bank, distributor or financial adviser.

Yours faithfully

Board

For and on behalf of Manulife Global Fund

* This website has not been reviewed by the SFC.